Shares of Esperion Therapeutics ESPR decreased after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share were down 72.12% over the past year to ($3.89), which missed the estimate of ($3.76).
Revenue of $9,638,000 up by 881.47% year over year, which missed the estimate of $12,520,000.
Looking Ahead
Esperion Therapeutics hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: Feb 23, 2021
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/h9ugsf9y
Technicals
Company's 52-week high was at $70.43
52-week low: $23.90
Price action over last quarter: Up 15.70%
Company Profile
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm has Business of researching, developing and commercializing therapies for the treatment of patients with the elevated LDL-C operating segment.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.